CD4 and neoplasm: oAd/IL12/GM-RLX showed enhanced ECM degradation, intratumoral penetration, and increased infiltration of CD4+ T cells and IFN-γ secretion. Combination treatment of oAd/IL12/GM-RLX and PD-1 blockade showed more potent inhibition of tumor growth compared to either treatment alone.